Fibroblast growth factor-1 is a mesenchymal stromal cell secreted factor stimulating proliferation of osteoarthritic chondrocytes  by Ling, W. et al.
Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312 S273cartilage secretome, for further analysis and also classiﬁcation of
unknown samples. This involved using label-free quantiﬁcation of
proteins identiﬁed in the secretome of canine articular cartilage, after
high throughput tandem mass spectrometry.
Methods: Canine cartilage explants, from dogs euthanased for purposes
other than research, were incubated in serum-free DMEM supple-
mented with 2% penicillin and streptomycin in a CO2 incubator for
24 hours at 37C. Explants were then incubated alone (control media),
or with recombinant canine IL-1b (10ng/ml), the non-steroidal anti-
inﬂammatory drug carprofen (Rimadyl, Pﬁzer Animal Health, 1 mg/ml)
or carprofen and IL-1b combined (1 mg/ml and 10ng/ml respectively).
After 5 days in culture, cell-free supernatants were removed and
representative samples were selected for proteomic analysis. Mascot
was used to analyse the data from each sample, in conjunctionwith the
Uniprot database, and the results were imported into the Trans-Pro-
teomic Pipeline (TPP). The emPAI protein quantiﬁcation scores from
Mascot and the ProteinProphet probabilities, for validation of protein
assignments, were recorded. Classiﬁcation models were built using the
rule-based machine learner BioHEL. Two datasets were formed, where
the proteins identiﬁed were associated with either emPAI scores or
ProteinProphet probabilities, across the twenty-three samples. Leave-
one-out cross validationwas used to validate the percentage accuracy of
themodels. To increase the classiﬁcation accuracy and identify potential
biomarkers, proteins were iteratively removed from the dataset and
only returned to the dataset if the classiﬁcation accuracy decreased
without them. In this way the accuracy was increased and the number
of proteins was greatly reduced to a small sub-set of proteins, which
provide an effective division of samples into their classes.
Results: This reduction technique increased the classiﬁcation accuracy
from 73.9% to 91.3% using the ProteinProphet probabilities and from
56.5% to 95.7% with the emPAI values. The ProteinProphet dataset was
reduced to six proteins, including matrix-metalloproteinase 3, inter-
leukin-8 and thrombospondin-1. The emPAI dataset achieved the
increased accuracy using only ﬁve proteins, which included clusterin
and matrix-metalloproteinase 3.
Conclusions: The machine learning based method discussed here has
been shown to be able to classify tandemmass spectrometry samples of
articular cartilage secretome. It was found that using ProteinProphet
probabilities, for each protein identiﬁed, gave a better classiﬁcation
than using the label-free quantiﬁcation method emPAI. However, this
was on a small dataset, of only twenty-three samples across four
classes, and therefore this method should be tested on a larger dataset
in the future. Finally, any proteins in the reduced datasets require
further analysis to determine their suitability as biomarkers.
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FIBROBLAST GROWTH FACTOR-1 IS A MESENCHYMAL STROMAL
CELL SECRETED FACTOR STIMULATING PROLIFERATION OF
OSTEOARTHRITIC CHONDROCYTES
W. Ling, J.C. Leijten, J.N. Post, M. Karperien. Univ. of Twente, Enschede,
The Netherlands
Purpose: Intra-articular injection of human mesenchymal stromal cells
(MSCs) is currently under investigation for disease modifying treatment
of osteoarthritis. In vitro experiments have shown beneﬁcial effects of
MSCs on chondrocytes in a variety of co-culture models in terms of
cartilage matrix formation. We have shown that in pellet co-cultures
this beneﬁcial effect with respect of cartilaginous matrix formation is
predominantly due to stimulation of chondrocyte proliferation by the
MSCs rather than to chondrogenic differentiation of the MSCs them-
selves. In addition, we have shown that this beneﬁcial effect on chon-
drocyte proliferation in pellet cultures is mainly due to the secretion of
(a) soluble factor(s) by the MSCs. The objective of this study is to
identify this factor(s) which may be (an) important mediator(s) of the
disease modifying trophic role of MSCs in osteoarthritis.
Methods: Human primary chondrocytes (hPCs) isolated from late stage
osteoarthritis patients were used in pellet co-culture with human bone
marrow derived MSCs (hMSCs). DNA microarray experiments were
performed to investigate the gene expression proﬁles of co-culture and
mono-culture pellets (hPCs or hMSCs respectively). Quantitative poly-
merase chain reaction (qPCR) and species speciﬁc PCR in co-culture
pellets of hMSCs and bovine PCs were carried out to validate microarray
data. Immunoﬂuorescent staining combined with cell tracking and
Enzyme-linked immunosorbent assay (ELISA) were performed to
conﬁrm the expression of candidate genes at the protein level. Chemicalblockers and neutralizing antibodies were used to study the functions of
candidate genes in co-cultures.
Results: Microarray data revealed a number of candidate secreted
soluble factors. Of these, Fibroblast Growth Factor-1 (FGF-1) mRNA
expression was markedly increased in co-culture pellets. Species
speciﬁc PCR in xenogenic co-culture pellets of bovine PCs and MSCs
conﬁrmed the upregulation of Fgf1 mRNA in the MSCs. Immunoﬂuo-
rescent staining in combination with cell tracking experiments
conﬁrmed the up-regulation of FGF-1 in co-culture pellets particularly
in the MSC cell fraction. Interestingly, FGF-1 expression was highest in
MSCs in direct contact with hPCs. ELISA demonstrated increased FGF-1
secretion in medium of pellet co-cultures only. Interestingly, blocking of
FGF signaling in co-culture pellets by speciﬁc FGF receptor inhibitors or
FGF-1 neutralizing antibodies completely abolished chondrocyte
proliferation. Likewise, neutralizing FGF-1 activity in MSC conditioned
medium by anti-FGF-1 antibodies also completely blocked chondrocyte
proliferation.
Conclusions:Wedemonstrate that MSCs increase FGF-1 secretion upon
co-culturewith chondrocytes, which in turn is responsible for increased
chondrocyte proliferation in these co-culture pellets. Our study iden-
tiﬁes FGF-1 as a potent trophic mediator of the proposed beneﬁcial
effects of intra-articular injected MSCs in the osteoarthritic joint which
may contribute to cartilage regeneration.
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COMPARISON OF NEUROMUSCULAR AND QUADRICEPS
STRENGTHENING EXERCISE IN PEOPLE WITH MEDIAL KNEE
OSTEOARTHRITIS AND VARUS MALALIGNMENT: RANDOMISED
CONTROLLED TRIAL
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Purpose: People with medial knee OA and varus malalignment are at
greater risk of structural disease progression than those with more
neutral alignment. This may be partly due to higher knee loads.
Quadriceps strengthening exercise, a cornerstone of OA treatment, has
been shown to be ineffective at reducing knee load and pain in people
with varus malalignment. Neuromuscular exercise may be more effec-
tive as it aims to improve quality of movement performance. This study
tested the hypothesis that a neuromuscular exercise program (NEXA)
would lead to greater reductions in peak knee adduction moment and
greater improvements in pain and physical function than traditional
quadriceps strengthening (QS) in people with medial knee joint OA and
varus malalignment.
Methods: This 12-week randomised, assessor-blinded, controlled trial
recruited 100 people with medial knee pain, radiographic medial
compartment OA and varus malalignment from the community.
Participants were randomly allocated to one of two 12-week exercise
programs. Each involved 14 supervised exercise sessions with a phys-
iotherapist plus home exercises 4 times/week. NEXA included weight-
bearing, functional exercises to improve quality of performance,
keeping the knee aligned over the foot throughout. The QS program
included nonweight-bearing exercises. Gradual progression of exercises
was made in both groups. Primary outcomes were medial knee load
during walking (peak external knee adduction moment (KAM) from 3D
gait analysis), average knee pain (100 mm visual analogue scale) and
self-reported physical function (WOMAC). Secondary outcomes were
external KAM angular impulse, knee ﬂexion moment, global rating of
change, knee/hip muscle strength, balance, function, and quality-of-life.
For continuous outcomes, differences in mean change (baseline minus
follow-up) were compared between groups using analysis of covariance
adjusted for baseline values. The sample size was powered to ﬁnd
clinically important differences in pain and function and a 7.5% differ-
ence in KAM.
Results: Of the 999 volunteers, 899 (90%) were ineligible or did not
wish to participate. In total, 100 participants (50 NEXA, 50 QS) were
randomised and 82 (38 (76%) NEXA, 44 (88%) QS) completed the trial.
The cohort were aged 62.5 (7.4) years, 52%were female and xray disease
severity showed 22% had KL grade 2, 43% KL grade 3 and 35% KL grade 4.
There were no signiﬁcant differences in change between groups in
any primary (Table) or secondary outcomes except for greater
